[Measurement and analysis of different serum PSA in patients with benign prostatic hyperplasia].
OBJECTIVE
To analyze the stability of different serum prostate-specific antigens (PSA) in patients with benign prostatic hyperplasia (BPH), and investigate their application value in the diagnosis of prostate disease.


METHODS
One hundred and five patients with BPH were divided into 3 groups by their total PSA (tPSA) level, 67 in group A (tPSA < 4 micrograms/L), 26 in group B (4 micrograms/L < or = tPSA < or = 10 micrograms/L) and 12 in group C (tPSA > 10 micrograms/L). These patients were also divided into another 3 groups by age, 18 in group a (< or = 55 years old), 33 in group b (from 56 to 69 years old) and 54 in group c (> or = 70 years old). tPSA, free PSA (fPSA) and complexed PSA (cPSA) were measured by magnetism-particulate-immuno-chemistry luminescence method, the ratios of cPSA/tPSA, fPSA/tPSA, fPSA/cPSA were calculated in 105 patients with BPH, and their stabilities were compared in different tPSA level and age groups.


RESULTS
The ratios of cPSA/tPSA, fPSA/tPSA and fPSA/cPSA were steadier than other PSAs in different tPSA level and age groups with BPH.


CONCLUSIONS
The ratios of cPSA/tPSA, fPSA/tPSA and fPSA/cPSA probably have more application value in the diagnosis of prostate disease.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis
D017430:Prostate-Specific Antigen